Clinical Trials Logo

Mild Cognitive Impairment clinical trials

View clinical trials related to Mild Cognitive Impairment.

Filter by:

NCT ID: NCT00134953 Terminated - Cognitive Symptoms Clinical Trials

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

Start date: January 2003
Phase: Phase 3
Study type: Interventional

This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).

NCT ID: NCT00091468 Active, not recruiting - Clinical trials for Age-Related Memory Disorders

Nicotine Treatment of Mild Cognitive Impairment (MCI)

Start date: September 2003
Phase: Phase 1
Study type: Interventional

The purpose of this 12-month study is to determine whether nicotine, administered in the form of nicotine patches, can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI).

NCT ID: NCT00040443 Completed - Clinical trials for Mild Cognitive Impairment

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Start date: April 2002
Phase: Phase 2
Study type: Interventional

Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.

NCT ID: NCT00000173 Completed - Alzheimer Disease Clinical Trials

Memory Impairment Study (Mild Cognitive Impairment Study)

Start date: March 1999
Phase: Phase 3
Study type: Interventional

The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.